Abstract 5924
Background
Due to their advanced age many cancer patients with unfavorable prognosis suffer from comorbidities, and thus the risk of consuming potentially inappropriate medication (PIM). It is vital to deprescribe drugs with potential harmful effects or no short-term benefit for lowering pill.
Hence, we examined the degree of deprescription of potentially inappropriate medication (PIM) in patients suffering from cancer.
Methods
Retrospective, register-based study of all patients with newly diagnosed breast, prostate, pancreatic, and lung cancer, diagnosed at a hospital in the Capital Region of Denmark (1.8 million inhabitants) from 2012-2014. Patients with insufficient staging information or other malignancy except non-melanoma skin-cancer were excluded. Information about medication, comorbidity and mortality was extracted from the electronic health records.
PIM were defined as: acetylsalicylic acid, calcium channel blockers, statins, thiazides, and bisphosphonates. The study was approved by the Danish Patient Safety Authority (No. 3-3013-1884/1/) and the Danish Data Protection Agency (No. BFH-2016-058).
Results
Table:
1607P
Breast (n = 3,959)/prostate cancer (n = 3,535) (total n = 7,494) | Lung (n = 2,824)/pancreatic cancer (n = 617) (n = 3,441) | |
---|---|---|
Gender (Women) | 52% | 50% |
Age mean (sd) | 65 (12) | 70 (10) |
1-year Survival | 97% | 46% |
Metastatic disease | 6.7% | 52% |
Co-morbidities | ||
Diabetes | 4.0 % | 9.7 % |
Hypertension | 12 % | 23 % |
Atrial fibrillation | 4.7 % | 8.7 % |
Ischemic heart disease | 6.4 % | 11.6 % |
Heart failure | 2.2 % | 5.6 % |
Ischemic stroke | 1.5 % | 2.8 % |
Medication | 1-year deprescription/total treated§ | |
Acetylsalicylic acid | 250/1,443 (17%) | 398/928 (43%) |
Calcium channel blockers | 135/1,048 (13%) | 284/659 (43%) |
Statins | 187/1,769 (11%) | 501/1,066 (47%) |
Thiazide diuretics | 175/954 (18%) | 259/534 (49%) |
Bisphosphonates | 26/319 (8.2%) | 64/171 (37%) |
Deprescribed during the first year after cancer-diagnosis/total number of patients treated
(Patients not surviving 1 year and treatment continuing until death does not count towards deprescribed)
Conclusions
Our findings show that oncologists and physicians have a rational approach to deprescription in patients suffering from cancer with short-term (pancreatic and lung cancer) respectively long-term (breast and prostate cancer) survival rates. However, several patients were continuing potential inappropriate medications in the terminal stage of cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract